Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis

Wang, Wei; Cao, Kejiang; Jin, Shengming; Zhu, Xiaoli; Ding, Jiale; Peng, Weijun

doi:10.1007/s00330-020-06896-5

Cited by 49 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some scholars establish that the short-term curative effect after microwave ablation therapy is mainly judged by imaging examination of tumor area after treatment and rebiopsy of suspected tumor residual site, but blind puncture biopsy of suspected tumor residual site has great one-sidedness; therefore, in order to ensure a good therapeutic effect and reduce the incidence of incomplete local ablation after microwave ablation, an imaging examination method which can objectively, comprehensively, and accurately evaluate the extent of tumor ablation and the efficacy of local ablation is needed [13]. e commonly used imaging evaluation methods after local microwave ablation of renal tumor include ultrasound, CT, and MRI [14,15]. Nevertheless, the ultrasound resolution is low, and it is unclear for the small residual tumors after microwave ablation, and the value for monitoring the efficacy of microwave ablation in the treatment of stage I renal clear cell carcinoma is relatively small [16].…”

Section: Introductionmentioning

confidence: 99%

Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging

Zhu

Chen

Wang

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

We have proposed an effective mechanism to corroborate the efficacy of microwave ablation (MA) in the treatment of stage I renal clear cell carcinoma in this paper. For this purpose, a total of 96 patients with stage I renal clear cell carcinoma presented in our hospital from May 2018 to January 2021 were randomly divided into CT group (n = 48) and MRI group (n = 48). Patients in both groups were treated with microwave ablation after pathological diagnosis. Patients in the CT group received enhanced CT examination to monitor the therapeutic effect; in contrast, patients in the MRI group received MRI examination to monitor their therapeutic effect. The focus areas before and after tumor microwave ablation were compared between the two groups. The patients were followed up to 1 year after the operation, and the microwave ablation inactivation rates of the two groups were compared according to the postoperative follow-up results. There was no significant difference between CT and MRI in the levels of long and short diameter before and after microwave ablation of renal clear cell carcinoma (P > 0.05). In the CT group, CT examination was performed within 24 hours after microwave ablation treatment, and 44 of 48 ablation lesions showed complete ablation. The remaining 4 lesions showed nodular heterogeneous enhancement in the arterial phase, indicating that the tumor remained. Microwave ablation was performed on the residual lesions during the operation, and then enhanced CT was performed again to show that the lesions were ablated completely. In the MRI group, MRI examination was performed within 24 hours after microwave ablation treatment, and 45 of 48 ablation lesions showed complete ablation. The remaining 3 lesions showed nodular heterogeneous enhancement in the arterial phase, indicating that the tumor remained. Microwave ablation was performed on the residual lesions during the operation, and MRI examination showed that the lesions were ablated completely. The patients were followed up to 1 year after the operation, and the microwave ablation inactivation rate of the two groups was compared according to the postoperative follow-up results as the gold standard. The inactivation rate of microwave ablation in the CT group was 89.58 (43/48). The inactivation rate of microwave ablation in the MRI group was 100.00% (48/48). The inactivation rate of microwave ablation in the MRI group was higher than that in the CT group (χ2 = 5.275, P = 0.021).

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging

Zhu

Chen

Wang

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Overall, imaging innovations showing future promise are represented by: (1) application of radiomics and DL algorithms to MRI and CT for differentiation of RCC subtypes [71,77,78,82] or of RCC from benign renal tumours [57,58,61,65,79] and stratification by tumour grade [68,70,72,74,85,86]; (2) the MRI-based clear-cell likelihood score for identification of ccRCC [67,76,83]; (3) analysis of the dynamic vascular pattern of renal masses on CEUS to predict RCC versus other tumour histotypes [56,59]; and (4) use of 99m Tc-sestamibi SPECT/CT imaging for diagnosis of RO and hybrid oncocytic/chromophobe tumours [64].…”

Section: Studies and Clinical Trials On Innovative Imaging For Kidneymentioning

confidence: 99%

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature

Campi

Stewart

Staehler

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

“…A variety of new MRI techniques, including intravoxel incoherent motion, diffusion kurtosis, texture analysis, arterial spin labelling, blood oxygenation level-dependent MRI and radiomics have been introduced for renal mass characterization, evaluation of RCC aggressiveness, and assessment of treatment response, although validation is needed [146][147][148][149][150][151]. Moreover, investigation of the biochemical environment of renal masses by proton MR spectroscopy may additionally help in lesion characterization [152].…”

Section: Multiparametric Mrimentioning

confidence: 99%

The role of imaging in the management of renal masses

Tsili

Andriotis

Gkeli

et al. 2021

European Journal of Radiology

View full text Add to dashboard Cite

The wide availability of cross-sectional imaging is responsible for the increased detection of small, usually asymptomatic renal masses. More than 50 % of renal cell carcinomas (RCCs) represent incidental findings on noninvasive imaging. Multimodality imaging, including conventional US, contrast-enhanced US (CEUS), CT and multiparametric MRI (mpMRI) is pivotal in diagnosing and characterizing a renal mass, but also provides information regarding its prognosis, therapeutic management, and follow-up. In this review, imaging data for renal masses that urologists need for accurate treatment planning will be discussed. The role of US, CEUS, CT and mpMRI in the detection and characterization of renal masses, RCC staging and follow-up of surgically treated or untreated localized RCC will be presented. The role of percutaneous image-guided ablation in the management of RCC will be also reviewed.

show abstract

Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis

Cited by 49 publications

References 42 publications

Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging

Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature

The role of imaging in the management of renal masses

Contact Info

Product

Resources

About